Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET

Company Participants

Todd Friedman - Director, Investor Relations

Christian Henry - President and Chief Executive Officer

Susan Kim - Chief Financial Officer

Conference Call Participants

Matt Sykes - Goldman Sachs

Kyle Mikson - Canaccord

Jack Meehan - Nephron Research

Daniel Brennan - TD Cowen

Sung Ji Nam - Scotiabank

Luke Sergott - Barclays

Rachel Vatnsdal - JP Morgan

Tejas Savant - Morgan Stanley

Ross Osborn - Cantor Fitzgerald

Operator

Hello and welcome to the PacBio Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this conference is being recorded.

I would now like to turn the call over to Todd Friedman, Head of Investor Relations.. Please go ahead.

Todd Friedman

Thanks MJ. Good afternoon and welcome to PacBio's second quarter 2023 earnings conference call. Earlier today, we issued a press release outlining the financial results, we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov.

With me today are Christian Henry, President and Chief Executive Officer and Susan Kim, Chief Financial Officer.

Before we begin, I'd like to remind you that on today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations regarding our financial guidance and operating plans, our Revio and Onso systems and their commercialization plans, the future availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using PacBio products or technologies, including our Revio and Onso systems, expectations with respect to our acquisition of Apton Biosciences and its products and technologies and active patients with respect to customer demand of our products and technologies and growth in our business.

You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks and uncertainties that could cause our actual results to differ materially from those projected or discussed, including those inherent in developing and commercializing new products. We refer you to our documents that we have filed with the SEC, including our most recent forms 10-Q and 10-K, and our recent press release to better understand the risks and uncertainties that could cause actual results to differ. We disclaim any obligation to update or revise these forward-looking statements except as required by law.